CardiaTec was established in September 2021 as a spin-out from the University of Cambridge by co-founders Raphael Peralta, Thelma Zablocki, and Professor Namshik Han. In an indication of the company’s achievements, Raphael and Thelma have recently been recognised as leading entrepreneurs in the prestigious Forbes 30 Under 30 Europe list for Science and Healthcare 2024.
The company leverages large and high-dimensional human multi-omics data to better navigate complex disease biology to identify novel and differentiated therapeutics. Its backers are Apex Ventures, Laidlaw Ventures, Cambridge Enterprise, Crista Galli Ventures and O2h Ventures.
CardiaTec recognises the strategic advantages of the BioEscalator ecosystem and has decided to establish its presence in Oxford to benefit from state-of-the-art laboratory facilities and proximity to expertise. The team is forging collaborations with leading Oxford University researchers and facilities, and commercial partners.
Co-founders
CEO & Co-Founder of CardiaTec Biosciences. Alumni of the MPhil in Bioscience Enterprise, University of Cambridge.
COO & Co-Founder of CardiaTec Biosciences. Alumni of the MPhil in Bioscience Enterprise, University of Cambridge.
Group Leader at Milner Institute, Associate Faculty at Centre for AI in Medicine, and Affiliated Principal Investigator at Stem Cell Institute, University of Cambridge & Founder and CTO of CardiaTec & Founder of KURE.ai